S65487

P1, N=60, Terminated, Institut de Recherches Internationales Servier | Completed --> Terminated; The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns.

P1, N=37, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business reasons

P1/2, N=57, Active, not recruiting, Institut de Recherches Internationales Servier | Recruiting --> Active, not recruiting | N=109 --> 57

P1/2, N=109, Recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jan 2026 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024

P1, N=60, Completed, Institut de Recherches Internationales Servier | Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023

P1, N=37, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Dec 2023 --> Jun 2024

P1, N=37, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2023 --> Apr 2024

P1, N=37, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2024 --> Dec 2023 | Trial primary completion date: Sep 2024 --> Dec 2023

P1/2, N=83, Recruiting, Institut de Recherches Internationales Servier | N=62 --> 83 | Trial completion date: Jun 2025 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Feb 2024

Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat were observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665. Altogether, these data demonstrate that S65487/VOB560 has significant therapeutic potential against human lymphoid and myeloid malignancies as well as in patients with Venetoclax resistant leukemias. Clinical studies are currently ongoing with S65487/VOB560 (NCT03755154).